Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving
health through innovative tests that guide patient care, recognizes
the importance of Esophageal Cancer Awareness Month and is
providing its support of key programs and initiatives throughout
the month of April. The Company is proud to continue its ongoing
collaboration with the Esophageal Cancer Action Network (ECAN),
Gastro Broadcast podcast and EndoscopyNow to help advance
esophageal cancer research, prevention, education and advocacy.
“Unfortunately, esophageal cancer is often detected at its late
stages and the five-year survival rate of esophageal cancer
patients is less than 20%,”1 said Emmanuel Gorospe, M.D., MPH, CPI,
FACP, FACG, FASGE, GI Medical Director at Castle Biosciences.
“Therefore, prevention and early detection are key. We are proud to
continue efforts to promote awareness of the disease and provide
holistic support directed towards patients as well as the GI
professional community through research, advocacy and educational
initiatives.”
Detection of esophageal cancer and its precursor, Barrett’s
esophagus (BE), is challenging because the primary symptoms —
heartburn and gastroesophageal reflux disease (GERD) — are common
to a multitude of less serious ailments that are typically not
cause for concern. TissueCypher® is Castle’s prognostic
risk-stratification test designed to predict progression to
high-grade dysplasia or esophageal cancer.
Esophageal Cancer Action Network (ECAN)
Castle is collaborating with ECAN’s Steps to Save Lives,
a virtual 5k run/walk/roll and the organization’s signature
fundraising event, being held April 21–28, 2024. For more
information or to get involved, visit ECAN’s Steps to Save Lives
page.
“When ECAN began Esophageal Cancer Awareness Month 15 years ago,
most people had never heard of, what was at the time, the
fastest-increasing cancer in the U.S. — up at least 600% in recent
decades — and today, esophageal cancer remains the
fastest-increasing cancer diagnosis among American men,”1 said
Mindy Mintz Mordecai, president and chief executive officer of
ECAN. “Thanks to the support of our corporate partners, not only
are more people becoming aware that reflux disease can cause this
devastating cancer, innovation by these companies is resulting in
better tests and tools that increase the chance that patients can
prevent this deadly disease before it starts.”
Gastro Broadcast
Castle is collaborating with Gastro Broadcast, a podcast
featuring independent GI physicians having conversations with their
colleagues, patient advocates and industry leaders on issues that
impact gastroenterology. For an April episode, Castle collaborated
with host, Dr. Naresh Gunaratnam of Huron Gastroenterology, who
interviewed Dr. Sri Komanduri, Associate Chief, Division of
Gastroenterology and Hepatology at the Feinberg School of Medicine
at Northwestern University, to discuss efforts to educate the
public about esophageal cancer and tools that can identify and
stratify risk for the disease in patients with BE.
EndoscopyNow
Castle is collaborating with EndoscopyNow, a mobile application
used among the GI professional community, and in April, is
sponsoring EndoscopyNow’s first “Masters in Endoscopy” webinar,
titled “Current Gaps and Risk Stratification in Barrett's
Esophagus.” Presented by Dr. Sri Komanduri, the webinar will take
place Wednesday, April 10, 2024, at 7:00 p.m. Eastern time.
Register for the webinar here or access it on demand in the
EndoscopyNow app following the broadcast.
About Esophageal Cancer Action Network
The Esophageal Cancer Action Network (ECAN) is a non-profit, 501
(c)(3) organization supporting esophageal cancer patients and their
families. Their mission is to save lives by 1) increasing awareness
about the link between Reflux Disease and Cancer, 2) promoting
early detection, 3) supporting medical innovation to prevent,
detect, treat and cure Esophageal Cancer, and 4) providing patients
and families with the latest, most reliable medical information and
compassionate support. ECAN’s relentless advocacy has increased the
federal budget for Esophageal Cancer research by more than $15
million in the past three years, and millions more is expected in
the years to come. Visit https://ecan.org/ for more
information.
About Gastro Broadcast
Gastro Broadcast Independent GI Radio is a twice-monthly podcast
featuring independent GI physicians and administrative leaders
having conversations with their colleagues on issues that impact
gastroenterology. While they may discuss treatment programs or
innovative patient care in certain GI practices, Gastro Broadcast
mostly explores how GI physicians navigate medicine, business,
practice management, policy advocacy and many other issues they
face in today’s healthcare environment. Access episodes online at
https://gastrobroadcast.com/ or through 3rd party applications
Apple Podcasts, Google Podcasts and Spotify.
About EndoscopyNow
The EndoscopyNow digital platform is a specialty-agnostic mobile
application presenting news, clinical data, procedural insights,
and product information to the global GI endoscopy community. To
learn more about EndoscopyNow, visit www.EndoscopyNow.com.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics
company improving health through innovative tests that guide
patient care. The Company aims to transform disease management by
keeping people first: patients, clinicians, employees and
investors.
Castle’s current portfolio consists of tests for skin cancers,
Barrett’s esophagus, mental health conditions and uveal melanoma.
Additionally, the Company has active research and development
programs for tests in other diseases with high clinical need,
including its test in development to help guide systemic therapy
selection for patients with moderate-to-severe atopic dermatitis,
psoriasis and related conditions. To learn more, please visit
www.CastleBiosciences.com and connect with us on LinkedIn,
Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath
Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM,
DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle
Biosciences, Inc.
1. Esophageal Cancer Action Network; https://ecan.org/; accessed
4/10/24
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240410800879/en/
Investor Contact: Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact: Allison Marshall
amarshall@castlebiosciences.com
Castle Biosciences (NASDAQ:CSTL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Castle Biosciences (NASDAQ:CSTL)
Historical Stock Chart
From Sep 2023 to Sep 2024